Eli Lilly scored a 100 on the 2023 Corporate Equality Index (CEI) from the Human Rights Campaign (HRC), a political stakeholder group. By complying with the HRC’s controversial demands, Eli Lilly increases the risk of dividing employees, alienating customers and harming shareholders. The company covers transgender-related medical costs for its employees and their children and provides specific sexual orientation and gender identity-based benefits. It also uses sex and gender ideology criteria in employee recruitment, vendor selection, marketing, and philanthropic support. Eli Lilly forces employees to undergo multiple ideological trainings and uses its reputation, corporate funds, and political influence to support controversial sex and gender ideologies, organizations, and legislation. Eli Lilly has also spoken out against state efforts to reform its own election processes. The company pledged $25 million to BLM and related causes and denounced religious freedom legislation. Eli Lilly has also funded Planned Parenthood and multiple LGBT organizations. For these reasons, Eli Lilly receives a High Risk rating.